Answer
Regorafenib (Stivarga) monotherapy is indicated for adults with unresectable or metastatic gastrointestinal stromal tumours who progressed on or are intolerant to prior treatment with imatinib and sunitinib.
Sources for this answer
- Stivarga 40 mg film coated tabletsBayer plc · emc · SmPC §4.1 Therapeutic Indications · Version 7Document updated
Sources checked